Answers are grounded in this paper and cite their sources.
Randomized trial demonstrates reduced exacerbation in eosinophilic COPD, suggesting effective treatment.
Mepolizumab reduces the time to first moderate or severe exacerbation and prolongs symptom-free periods in patients with eosinophilic COPD, without increasing the risk of AEs.
No takes yet. Share an insight, caveat, or question.
Bisht et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: